Navigation Links
Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
Date:10/18/2010

DURHAM, N.C., Oct. 18 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present an overview of its Arcelis™ dendritic cell-based immunotherapy at 3:30 p.m. EDT on Oct. 21 at the inaugural Cancer Immunotherapy Conference in New York.

In addition, Charles Nicolette, Ph.D., the company's chief scientific officer and vice president of research and development, will participate in a panel discussion titled "Autologous versus allogeneic immunotherapy" at 2:45 p.m. EDT that day. The conference will take place at the New York Academy of Medicine. A live Webcast of the conference can be accessed by visiting www.mdbpartners.com/vaccine.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy company developing new treatments for cancer
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
2. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
3. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
4. Prime Therapeutics Announces URAC Accreditation
5. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
6. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
7. Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
8. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
9. Prime Therapeutics Hires Peter Wickersham, Senior Vice President Cost of Care
10. Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill
11. Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Inc. (NASDAQ: UPI ), a medical device ... products to treat voiding dysfunctions, today reported financial ... 30, 2014.  Global revenue for the ... to $4.1 million, as compared to $3.4 million ... Total revenue for the fiscal first quarter of ...
(Date:7/24/2014)... , July 24, 2014 Amgen (NASDAQ: ... second quarter financial results on Tuesday, July 29, 2014, after ... be followed by a conference call with the investment community ... will be Robert A. Bradway , chairman and chief ... Live audio of the conference call will be ...
(Date:7/24/2014)... and MENLO PARK, Calif. , ... (OTCQB: DMPI) ("DelMar" "the company") announced today that the company,s ... year from December 31 to June 30. Accordingly, DelMar will ... 2014. Jeffrey Bacha , president and CEO ... an important step in achieving our goal of obtaining a ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... shows,significant 35% reduction in subsequent osteoporotic fractures with Reclast -- ... 28% reduction in overall mortality seen in study patients ... treated with Reclast, -- ... fracture despite high risk of morbidity and mortality (1) -- ...
... (Nasdaq: TGEN ) today reported on the ... (NIH) Recombinant DNA Advisory,Committee (RAC), which reviewed the ... death of a patient participating in the,Company,s Phase ... The clinical case was presented for the first ...
Cached Medicine Technology:First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 2First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 3First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 4First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 5First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 6First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 7First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 8Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis 2Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis 3Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis 4
(Date:7/24/2014)... Primary care treatment of overweight and obese preschoolers ... compared to when only the child is targeted, according ... and conducted at the University at Buffalo and Women ... study were overweight or obese and had one parent ... or obese, according to body mass index (BMI) measurements, ...
(Date:7/24/2014)... positive outcomes experience paradoxical feelings of pleasure and ... of the brain, according to research led by ... Princeton Neuroscience Institute at Princeton University. , ... of more than 300 products using an auction-like ... products with different or similar values and were ...
(Date:7/24/2014)... In signing the Workforce Innovation and ... Atlanta BeltLine Workforce Partnership in Healthcare as one ... ( http://www.whitehouse.gov/ready-to-work ). The Administration called for ... economic strategy and profiled successful local efforts to ... Obama highlights the power of partnerships in Atlanta,” ...
(Date:7/24/2014)... 2014 In a recent report by CBS ... put an end to criminal penalties associated with possession of ... for marijuana reform in Washington DC, giving it one of ... replaces criminal penalties for possession of one ounce of marijuana ... possession of more than an ounce of marijuana remain criminal ...
(Date:7/24/2014)... 24, 2014 According to market ... Models, Technology Roadmap, Forecasts and Analysis - 2018", ... expected to reach $7.7 billion by 2018 at ... Browse 102 market data tables and 30 figures ... “3D Mapping Market: Global Advancements, Business Models, Technology ...
Breaking Medicine News(10 mins):Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Washington D.C. Decriminalizes Marijuana 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4
... spinal fluid seem likely candidates, researchers say , , TUESDAY, July ... hunt for biomarkers for Alzheimer,s disease. , A biomarker -- ... of what,s going on inside the body -- will help ... have better drugs for Alzheimer,s, with earlier intervention in the ...
... fibrosis (CF) has successfully corrected the defect which causes ... by Dr. Richard Rozmahel, a scientist with the Lawson ... Ontario, has clear implications to understanding and treating this ... a fatal, genetic disease characterized by an overproduction of ...
... ... Costs Can Be Avoided with Proper Treatment and Prevention ... Initiatives, NEW BRUNSWICK, N.J., July 29 ... economy of the most common chronic diseases is calculated to be,$39 billion. In the U.S. ...
... ROCKVILLE, Md., July 29 Sanaria Inc., ... the University of,Maryland Biotechnology Institute (UMBI) announced ... Research (SBIR) Grant from the,National Institute of ... Institutes of Health. The grant will support ...
... Medical Center of Santa Rosa, SANTA ROSA, Calif., ... United Healthcare Workers - West:, Healthcare workers will ... alarm at a growing healthcare crisis in Sonoma,County that ... next,month. The announced elimination of 120 SMCSR workers would ...
... cyberinfrastructure the organized aggregate of information technologies, organizations, ... advancement and discovery. In this month,s EDUCAUSE ... Supercomputer Center (SDSC) at the University of California, San ... part of the "IT bill" for the Information Age. ...
Cached Medicine News:Health News:'Biomarkers' May Help Spot, Track Alzheimer's 2Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 2Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 3Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 4Health News:Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant 2Health News:Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant 3Health News:Workers Denounce Sutter Health's Disregard for Community Interests 2Health News:San Diego Supercomputer Center director urges academia to make cyberinfrastructure 'real' 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: